1. Show article details.

    Viatris (VTRS) Surpasses Q2 Earnings Estimates

    Benzinga – 10:47 AM ET 08/08/2022

    Viatris came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.81 per share.

  2. Show article details.

    Viatris: Q2 Earnings Insights

    Benzinga – 7:25 AM ET 08/08/2022

      Viatris reported its Q2 earnings results on Monday, August 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Viatris beat estimated earnings by 6.02%, reporting an EPS of $0.88 versus an estimate of $0.83. Revenue was down $461.00 million from the same period last year.

  3. Show article details.

    BRIEF-Viatris reports Q2 Results

    Reuters – 7:09 AM ET 08/08/2022


  4. Show article details.

    Viatris Reports Strong Second Quarter 2022 Results

    PR Newswire – 6:59 AM ET 08/08/2022

    [1] Viatris (VTRS) is not providing forward-looking guidance for U.S. GAAP net earnings or a quantitative reconciliation of its 2022 adjusted EBITDA guidance. PITTSBURGH, Aug. 8, 2022 /PRNewswire/ -- Viatris Inc. (VTRS) today reported strong results for the second quarter of 2022 and provided an update to its full year 2022 financial guidance.

  5. Show article details.

    Earnings Scheduled For August 8, 2022

    Benzinga – 5:30 AM ET 08/08/2022

      ** Pyxis Tankers is likely to report earnings for its second quarter. ** Kandi Technologies Gr is projected to report earnings for its second quarter. ** Tredegar is estimated to report earnings for its second quarter. ** PowerFleet is likely to report quarterly loss at $0.12 per share on revenue of $34.36 million. ** PDS Biotechnology is projected to report earnings for its second quarter.

  6. Show article details.

    Recession Investing: 5 High Yield Dividend Stocks For A Downturn

    Benzinga – 2:23 PM ET 08/03/2022

    As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.

  7. Show article details.

    Biogen leans on new Alzheimer's drug to calm investor worries

    Reuters – 7:55 AM ET 07/20/2022

    Biogen Inc (BIIB) on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer's disease drug being developed with Eisai Co Ltd and promising to draw lessons from the setbacks to its treatment Aduhelm. Biogen also disclosed that it had agreed to pay $900 million to resolve a whistleblower lawsuit accusing it of paying doctors kickbacks to prescribe multiple sclerosis drugs.

  8. Show article details.

    Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022

    PR Newswire – 6:59 AM ET 07/01/2022

    PITTSBURGH, July 1, 2022 Viatris Inc.  plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial markets. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 866.342.8591 or 203.518.9713 for international callers.

  9. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022

    Benzinga – 10:03 AM ET 06/14/2022

    Evercore ISI Group upgraded the previous rating for US Silica Holdings Inc from In-Line to Outperform. According to B of A Securities, the prior rating for Tractor Supply Co was changed from Neutral to Buy. For NetApp Inc, Deutsche Bank upgraded the previous rating of Hold to Buy. CIBC upgraded the previous rating for Thomson Reuters Corp from Neutral to Outperformer.

  10. Show article details.

    Looking Into Viatris's Return On Capital Employed

    Benzinga – 11:42 AM ET 06/03/2022

    According to Benzinga Pro, during Q1, Viatris earned $399.20 million, a 251.33% increase from the preceding quarter. Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

  11. Show article details.

    Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

    PR Newswire – 5:30 PM ET 05/20/2022

    PITTSBURGH , May 20, 2022  Viatris Inc. , a global pharmaceutical company, today announced the company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, CA on Tuesday, June 14, 2022.

  12. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

    Benzinga – 10:17 AM ET 05/10/2022

    According to Nomura Instinet, the prior rating for Goodyear Tire & Rubber Co was changed from Neutral to Buy. For Fluent Inc, Barrington Research upgraded the previous rating of Market Perform to Outperform. Berenberg upgraded the previous rating for Healthcare Trust of America Inc from Hold to Buy.

  13. Show article details.

    Expert Ratings for Viatris

    Benzinga – 9:13 AM ET 05/10/2022

    Analysts have provided the following ratings for Viatris within the last quarter: In the last 3 months, 4 analysts have offered 12-month price targets for Viatris. Below is a summary of how these 4 analysts rated Viatris over the past 3 months.

  14. Show article details.

    Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

    Benzinga – 1:46 PM ET 05/09/2022

    Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

  15. Show article details.

    27 Recession-Resistant Stocks To Look At Now

    Benzinga – 1:26 PM ET 05/09/2022

    When we enter a period of economic uncertainty, the phrase "recession-proof stocks" is tossed about, but really the only certainty is that recession-proof stocks do not exist. On the other hand, recession-resistant companies are what a savvy investor searches for during the absence of a bull market, as we are now.

  16. Show article details.

    Recap: Viatris Q1 Earnings

    Benzinga – 7:10 AM ET 05/09/2022

      Viatris reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Viatris beat estimated earnings by 12.05%, reporting an EPS of $0.93 versus an estimate of $0.83. Revenue was down $208.00 million from the same period last year.

  17. Show article details.

    Earnings Scheduled For May 9, 2022

    Benzinga – 4:52 AM ET 05/09/2022

      ** Atlantica Sustainable is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. ** NAPCO Security is estimated to report quarterly earnings at $0.07 per share on revenue of $34.66 million. ** GEO Group is projected to report quarterly earnings at $0.10 per share on revenue of $39.26 million.

  18. Show article details.

    Viatris Q1 2022 Earnings Conference Call On May 9, 2022 At 08:30 AM ET

    Benzinga – 10:09 AM ET 05/04/2022

      Viatris will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. Follow this link to access the live webcast. To listen to the call, dial 866.342.8591 or 203.518.9713. Earnings conference calls allow companies to talk about their recent earnings reports publicly, so that anyone who is interested can get more information on what happened and why it happened.

  19. Show article details.

    Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label

    Benzinga – 9:04 AM ET 04/13/2022

    Mylan Pharmaceuticals Inc, a Viatris Inc  company, is voluntarily recalling one batch of its Insulin Glargine  Injection, 100 units/mL, which is packaged in a 10 mL vial that is inside a carton. 

  20. Show article details.

    The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

    Benzinga – 8:15 AM ET 04/13/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours. Halozyme Buys Specialty Product Company Antares In $960M Deal Halozyme Therapeutics Inc  will acquire Antares Pharma Inc  for $5.60 per share, valuing Antares at approximately $960 million.


Today's and Upcoming Events

  • Nov

    VTRS to announce Q3 earnings (Unconfirmed)

  • Aug

    VTRS ex-Dividend for $0.12 on 08/23/2022

    • Announce Date: 08/08/2022
    • Record Date: 08/24/2022
    • Pay Date: 09/16/2022

Past Events (last 90 days)

  • Aug

    VTRS announced Q2 earnings.

  • May

    VTRS ex-Dividend for $0.12 on 05/23/2022

    • Announce Date: 05/09/2022
    • Record Date: 05/24/2022
    • Pay Date: 06/16/2022
Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

See the Latest Features
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.